[Back to Contents Page]

 

Mini-Reviews in Medicinal Chemistry, Volume 4, No. 4, 2004

 

Contents

 

Pro-Nucleotide Development and Delivery of Biologically Active Nucleotide Analogues

Executive Editor: Chris Meier

 

The Role of Thymidine Kinases in the Activation of Pyrimidine Nucleoside Analogues  Pp. 341-350

Ashraf S. Al-Madhoun, Werner Tjarks and Staffan Eriksson

[Abstract]

 

Structural Requirements for Efficient Phosphorylation of Nucleotide Analogs by Human Thymidylate Kinase Pp. 351-359

Arnon Lavie and Manfred Konrad

[Abstract]

 

Antiviral Nucleoside Analogs Phosphorylation by Nucleoside Diphosphate Kinase Pp. 361-369

S. Gallois-Montbrun, M. Veron and D. Deville-Bonne

[Abstract]

 

Aryloxy Phosphoramidate Triesters as Pro-Tides Pp. 371-381

Dominique Cahard, Christopher McGuigan and Jan Balzarini

[Abstract]

 

“Lock-in”-cycloSal-Pronucleotides – A New Generation of Chemical Trojan Horses? Pp. 383-394

Chris Meier, Manuel F.H. Ruppel, Dalibor Vukadinovic and Jan Balzarini

[Abstract]

 

SATE Pronucleotide Approaches: An Overview Pp. 395-408

S. Peyrottes, D. Egron, I. Lefebvre, G. Gosselin, J.-L. Imbach and C. Perigaud

[Abstract]

 

Designing a Pronucleotide Stratagem: Lessons from Amino Acid Phosphoramidates of Anticancer and Antiviral Pyrimidines Pp. 409-419

Dan P. Drontle and Carston R. Wagner

[Abstract]

 

Discovery and Validation of a New Family of Antioxidants: The Aminopyrazine Derivatives Pp. 421-435

M.L.N. Dubuisson, J.-F. Rees and J. Marchand-Brynaert

[Abstract]

 

Bioactive Carbohydrates and Recently Discovered Analogues as Chemotherapeutics Pp. 437-459

Tanja M. Wrodnigg and Friedrich K. (Fitz) Sprenger

[Abstract]

 

Abstracts

 

[Back to top] The Role of Thymidine Kinases in the Activation of Pyrimidine Nucleoside Analogues

Ashraf S. Al-Madhoun, Werner Tjarks and Staffan Eriksson

 

Deoxynucleoside analogues need activation by deoxynucleoside kinases to serve as antiviral or anticancer agents. Here we review the properties of cellular cytoplasmic thymidine kinase 1, mitochondrial thymidine kinase 2, the multisubstrate deoxynucleoside kinase from Drosophila melanogaster and Herpes virus 1 thymidine kinase. Important substrate activity relationships will be discussed.

 

[Back to top] Structural Requirements for Efficient Phosphorylation of Nucleotide Analogs by Human Thymidylate Kinase

Arnon Lavie and Manfred Konrad

 

Successive phosphorylation of nucleoside analog prodrugs to their triphosphate forms is required for the pharmacological activity of these compounds in the chemotherapeutic treatment of viral infections and cancer. Human thymidylate kinase (TMPK), apart from its essential physiological role in the biosynthesis of TTP, is also required for the activation of thymidine analogs, such as the clinically used anti-HIV prodrugs AZT and d4T. This enzyme is rate determining in the three-step cascade of AZT phosphorylation. Our structural work on human, yeast and E. coli TMPKs, in conjunction with sequence homology analyses and biochemical data, has demonstrated that three loops are crucial for the function of this enzyme: the first is the highly conserved P-loop motif, which binds and positions the phosphoryl groups of ATP, the second critical loop contains the DR(Y/H) motif that supplies a catalytic arginine and is also important for the binding and positioning of the magnesium ion complexed to ATP, and the third loop is the so-called Lid-region that is a flexible stretch which closes on ATP when it binds. Modifications of the sugar moieties of nucleoside monophosphates are shown to exert drastic effects on the enzyme's conformation and, thus, reduced activity. Our structural work on several TMPKs has formed the basis for generating mutants of human TMPK that are about 100 times more efficient in phosphorylating AZTMP. These enzyme variants could potentially be introduced into HIV-targeted cells in order to significantly improve AZT's antiviral activity.

 

[Back to top] Antiviral Nucleoside Analogs Phosphorylation by Nucleoside Diphosphate Kinase

S. Gallois-Montbrun, M. Veron and D. Deville-Bonne

 

The reaction of NDP kinase was studied in vitro with several antiviral derivatives, using kinetic steady state and presteady state analysis. The enzyme is highly efficient with natural nucleotides but most of the analogs are slow substrates. The catalytic efficiency, also related to the affinity of the analog, is mainly dependent on the presence of a 3'-OH group on the ribose moiety.

 

[Back to top] Aryloxy Phosphoramidate Triesters as Pro-Tides

Dominique Cahard, Christopher McGuigan and Jan Balzarini

 

We herein describe the development of aryloxy phosphoramidate triesters as an effective pro-tide motif for the intracellular delivery of charged bio-active antiviral nucleoside monophosphates. The review covers the discovery of such aryl phosphoramidates, their mechanism of action and structure-activity relationships. The application of this strategy to a range of antiviral nucleosides is highlighted.

 

[Back to top] “Lock-in”-cycloSal-Pronucleotides – A New Generation of Chemical Trojan Horses?

Chris Meier, Manuel F.H. Ruppel, Dalibor Vukadinovic and Jan Balzarini

 

The cycloSal-concept is one example of a successful nucleotide delivering system (pronucleotide).For several nucleoside analogues, the cycloSal-approach improved the antiviral potency and the applicability of the nucleosides could be broadened. Here, a conceptional extension of the original design of the cycloSalsystem will be discussed.

 

[Back to top] SATE Pronucleotide Approaches: An Overview

S. Peyrottes,  D. Egron, I. Lefebvre, G. Gosselin, J.-L. Imbach and C. Perigaud

 

This review depicts in vitro and in vivo results obtained with nucleotide prodrugs (pronucleotides) bearing S-acyl-2-thioethyl (SATE) groups as esterase-labile phosphate protections. New developments are illustrated by the design of mononucleoside mixed phosphoester derivatives leading to the selective intracellular delivery of the corresponding 5'-mononucleotide through two different enzyme-mediated activation steps.

 

[Back to top] Designing a Pronucleotide Stratagem: Lessons from Amino Acid Phosphoramidates of Anticancer and Antiviral Pyrimidines

Dan P. Drontle and Carston R. Wagner

 

Phosphoramidate pronucleotides have proven to be an effective strategy for the intracellular delivery of nucleoside 5'-monophosphates. This review will summarize our efforts to understand the in vitro and in vivo behavior of phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT), 3'-fluoro-3'- deoxythymidine (FLT) and 5-fluoro-2'-deoxyuridine (FUdR). Insights drawn from these studies have proved valuable for the future design of phosphoramidate-based pronucleotides.

 

[Back to top] Discovery and Validation of a New Family of Antioxidants: The Aminopyrazine Derivatives

M.L.N. Dubuisson, J.-F. Rees and J. Marchand-Brynaert

 

Coelenteramine (2-amino-1,4-pyrazine derivative), one of the metabolites of the oxidative degradation of coelenterazine (imidazolopyrazinone derivative), is endowed with excellent antioxidative properties towards ROS/RNS, like its mother-compound. This crucial discovery, made during the study of natural bioluminescent compounds (luciferins), has stimulated the development of synthetic aminopyrazine derivatives as new leads in medicinal chemistry in the field of antioxidant-based therapies. Synthetic approaches, theoretical evaluation, radical scavenging properties in acellular and cellular tests, and in vivo evaluation are described, and illustrated with representative aminopyrazines. Tested compounds were inhibitors of lipid peroxidation and good quenchers of peroxynitrite. They efficiently protect isolated LDL against radical-induced damages. They prevent cell constituents (membranes, DNA) against injuries by various oxidative stressors (UV irradiation, hydroperoxide treatment, oxidized LDL toxicity). Lastly, aminopyrazines are remarkably active in the "hamster cheek pouch" assay (in vivo protection against ischemia-reperfusion damages).

 

[Back to top] Bioactive Carbohydrates and Recently Discovered Analogues as Chemotherapeutics

Tanja M. Wrodnigg and Friedrich K. (Fitz) Sprenger

 

Infectious diseases such as tuberculosis, malaria, the “simple flu” or HIV and HBV, are killing more than 50,000 people a day according to estimations by the World Health Organisation (WHO). Consequently, the development of biologically active agents in general, such as antibiotics and chemotherapeutics, is of great importance. Hand in hand with the understanding of the mechanisms of biological agents, structures carrying sugar moieties have become increasingly important during the last decades. This review will cover the most recent developments in the field of new antibiotics and synthetic agents containing carbohydrates which are active against tuberculosis and malaria. In addition, compounds having antiviral, antibacterial and anticancer properties will be examined. Compounds such as aminoglycosides, iminosugars, carbacycles, nucleosides, and other selected substance classes will be considered.